Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clostridium butyricum plus immune checkpoint inhibitor maintenance vs immune checkpoint inhibitor alone in extensive-stage small-cell lung cancer
ChiCTR2300071620Phase 4Not yet recruiting
- Sponsor
- Yunnan Cancer Hospital
- Start
- May 2023
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of clostridium butyricum in small cell lung cancer (SCLC) (2 arms), sponsored by Yunnan Cancer Hospital. Primary endpoint: Progression-free survival. Planned start May 2023; status: not yet recruiting.
02
Drugs
clostridium butyricum
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2300071620.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300071620.